{"id":56259,"date":"2026-02-04T20:48:35","date_gmt":"2026-02-04T12:48:35","guid":{"rendered":"https:\/\/flcube.com\/?p=56259"},"modified":"2026-02-04T20:48:38","modified_gmt":"2026-02-04T12:48:38","slug":"tennor-therapeutics-files-hong-kong-ipo-for-anti-infective-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56259","title":{"rendered":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline"},"content":{"rendered":"\n<p><strong>TenNor Therapeutics (Suzhou) Limited<\/strong> submitted its initial public offering (IPO) application to the <strong>Main Board of the Hong Kong Stock Exchange<\/strong>. Founded in <strong>2013<\/strong>, the biotech company is approaching commercialization with a pipeline focused on <strong>bacterial infections<\/strong> and <strong>bacterial metabolism-related diseases<\/strong>, including two core candidates in late\u2011stage development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-filing-amp-company-profile\">IPO Filing &amp; Company Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>TenNor Therapeutics (Suzhou) Limited<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2013<\/td><\/tr><tr><td><strong>IPO Venue<\/strong><\/td><td>Hong Kong Stock Exchange Main Board<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Bacterial infections and bacterial metabolism-related diseases<\/td><\/tr><tr><td><strong>Pipeline<\/strong><\/td><td>Seven innovative projects<\/td><\/tr><tr><td><strong>Financials<\/strong><\/td><td>RMB\u202f116\u202fM (USD\u202f16.7\u202fM) net loss for first three quarters of 2025<\/td><\/tr><tr><td><strong>Strategic Vision<\/strong><\/td><td>Commercial\u2011stage biotech addressing unmet needs in anti\u2011infectives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline-assets\">Core Pipeline Assets<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-rifasutenizol-tnp-2198-new-molecular-entity-nme\"><strong>Rifasutenizol (TNP-2198) \u2013 New Molecular Entity (NME)<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Novel anti\u2011infective targeting bacterial metabolism<\/li>\n\n\n\n<li><strong>Indications:<\/strong><\/li>\n\n\n\n<li><strong>Helicobacter pylori infection<\/strong> (combination with amoxicillin + PPI) \u2013 Phase III trials in China and US<\/li>\n\n\n\n<li><strong>Bacterial vaginosis<\/strong> \u2013 Monotherapy trials in China<\/li>\n\n\n\n<li><strong>Clostridioides difficile infection<\/strong> \u2013 Monotherapy trials in China<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tnp-2092-triple-target-candidate\"><strong>TNP-2092 \u2013 Triple\u2011Target Candidate<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Multi\u2011target approach for implant\u2011related bacterial infections<\/li>\n\n\n\n<li><strong>Indications:<\/strong><\/li>\n\n\n\n<li><strong>Acute bacterial skin and skin structure infections (ABSSSI)<\/strong><\/li>\n\n\n\n<li><strong>Prosthetic joint infections (PJI)<\/strong><\/li>\n\n\n\n<li><strong>Left ventricular assist device infections (LVADI)<\/strong><\/li>\n\n\n\n<li><strong>Central venous catheter\u2011related bloodstream infections (CRBSI)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Anti\u2011Infective Market:<\/strong> Valued at <strong>\u00a580\u202fbillion<\/strong> (~US$11\u202fbillion) in 2025, with growing resistance driving demand for novel mechanisms<\/li>\n\n\n\n<li><strong>H. pylori Opportunity:<\/strong> <strong>50%<\/strong> of Chinese population infected; rifasutenizol\u2019s novel mechanism could capture <strong>\u00a55\u20138\u202fbillion<\/strong> : market<\/li>\n\n\n\n<li><strong>Implant Infection Segment:<\/strong> Device\u2011related infections affect <strong>~2\u202fmillion<\/strong> : patients annually; TNP-2092 addresses critical unmet need<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.5\u20132.5\u202fbillion<\/strong> (US$210\u2013350\u202fmillion) peak sales for rifasutenizol by 2028; TNP-2092 could add <strong>\u00a51\u202fbillion+<\/strong> if approved<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> TenNor\u2019s NME approach differentiates from generic antibiotics; limited competition in bacterial metabolism space<\/li>\n\n\n\n<li><strong>IPO Use of Proceeds:<\/strong> Expected to fund Phase\u202fIII completion, manufacturing scale\u2011up, and TNP-2092 clinical advancement<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO timelines, clinical development plans, and revenue projections for TenNor\u2019s pipeline. Actual results may differ due to market conditions, regulatory review, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56260,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,72,2192],"class_list":["post-56259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-ipo","tag-tennor-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56259\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline\" \/>\n<meta property=\"og:description\" content=\"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56259\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T12:48:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T12:48:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline\",\"datePublished\":\"2026-02-04T12:48:35+00:00\",\"dateModified\":\"2026-02-04T12:48:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0404.webp\",\"keywords\":[\"Biotech\",\"IPO\",\"TenNor Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56259#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56259\",\"name\":\"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0404.webp\",\"datePublished\":\"2026-02-04T12:48:35+00:00\",\"dateModified\":\"2026-02-04T12:48:38+00:00\",\"description\":\"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56259\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0404.webp\",\"width\":1080,\"height\":608,\"caption\":\"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56259#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56259","og_locale":"en_US","og_type":"article","og_title":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline","og_description":"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.","og_url":"https:\/\/flcube.com\/?p=56259","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T12:48:35+00:00","article_modified_time":"2026-02-04T12:48:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56259#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56259"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline","datePublished":"2026-02-04T12:48:35+00:00","dateModified":"2026-02-04T12:48:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56259"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56259#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","keywords":["Biotech","IPO","TenNor Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56259#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56259","url":"https:\/\/flcube.com\/?p=56259","name":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56259#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56259#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","datePublished":"2026-02-04T12:48:35+00:00","dateModified":"2026-02-04T12:48:38+00:00","description":"TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange. Founded in 2013, the biotech company is approaching commercialization with a pipeline focused on bacterial infections and bacterial metabolism-related diseases, including two core candidates in late\u2011stage development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56259#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56259"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56259#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","width":1080,"height":608,"caption":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56259#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56259"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56259\/revisions"}],"predecessor-version":[{"id":56261,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56259\/revisions\/56261"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56260"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}